This bispecific VHH was shown to trigger activation of CD16+ NK cells, resulting in enhanced cytotoxicity of EGFR+ tumor cell lines and EGFR+ patient CRC specimens in both an autologous and allogeneic setting. This evidence concerns the gene FCGR3B and neoplasm.